adMare BioInnovations Leadership Announcement

Vancouver (BC), Toronto (ON), Montreal (QC), (March 31, 2026) — adMare BioInnovations today announced a leadership transition with Gordon McCauley moving from his role as founding President and CEO to Vice-Chair of the organization. In this role, he will remain actively engaged in advancing the organization’s strategic priorities, with particular focus on key stakeholder relationships and public policy at the federal and provincial levels.

As part of a succession plan initiated two years ago, adMare’s Board of Directors has appointed Matthew J. Carlyle as President, CEO, and Director, effective April 1, 2026. Carlyle has served as Chief Operating Officer for the past three years and has been a senior executive at adMare for nine years.

Reflecting on the transition, McCauley said:

“Over the past decade, I have been incredibly proud to work alongside the team that built adMare into Canada’s national platform for life sciences company creation. Matthew Carlyle is uniquely qualified to lead adMare into its next chapter, and I remain committed to continuing to support the organization and our public policy partners as we work together to deliver on Canada’s life science promise.”

With Carlyle assuming the role of President and CEO, adMare will continue to strengthen and add to its current portfolio of more than twenty high-potential Canadian companies, and support Canada’s life sciences ecosystem with turnkey lab space and talent development.

“Gordon and I are closely aligned in our vision for adMare and the Canadian life sciences industry,” said Carlyle. “Under Gordon’s leadership adMare has helped create 39 companies, that have attracted $2.5 billion in real risk capital, are worth $5.8 billion today and created 1,000 jobs. These outcomes reflect the strength of adMare’s model and the team’s ability to build strong, investable, Canadian life sciences companies”

 The organization has also generated more than $130 million in cash returns, putting it in a strong position to advance its mission of translating scientific breakthroughs into Canadian companies with global impact.

Paul Buron, Chair of adMare’s Board of Directors, added:

“This transition reflects a strong management team, governance, and continuity, and positions adMare well for sustained impact in Canada’s life sciences ecosystem. We are deeply grateful for Gordon’s leadership and vision in building adMare, and we look forward to Matthew’s continued impact.”

As part of the leadership transition, adMare has also announced the promotion of Frédéric Lemaître Auger to Executive Vice President, Investments.  “Since joining adMare six years ago, Frédéric has played an instrumental role in strengthening the organization’s investment strategy, portfolio performance and investment team,” said Carlyle.  “His promotion reflects both his leadership and the increasing scale and sophistication of our investment engine as we continue to build and grow Canadian life sciences companies.”

###

About adMare BioInnovations

adMare BioInnovations is Canada’s life sciences company creation engine, focused on building and scaling strong, investable companies. Our unique model identifies breakthrough innovations addressing unmet patient needs and supports early company creation and growth through pre-seed investment, commercial R&D and IP and business development expertise. This approach helps establish the scientific validation, value, and operating foundations needed to build globally competitive Canadian life science companies. To date, adMare has helped create 39 companies that have attracted $2.5 billion in risk capital, achieved a combined value of $5.8 billion, and created approximately 1,000 jobs.  

adMare also provides more than 200,000 square feet of turnkey lab facilities and delivers industry-ready talent and executive leadership development programs to help Canadian life science companies scale and succeed. Learn more at www.admarebio.com 

Media Contact

Bethany Moir  
Senior Director, Public Affairs 
adMare BioInnovations  
bmoir@admarebio.com